Impact of JAK-inhibitor therapy on inflammation-mediated comorbidities in MPNs

by Dr. Hans C Hasselbalch Chronic inflammation is suggested to contribute to the Philadelphia-chromosome-negative myeloproliferative neoplasm (MPN) disease initiation and progression, as well as the development of premature atherosclerosis and may drive the development of other cancers in MPNs, both nonhematologic and hematologic. The MPN population has a substantial comorbidity burden, including cerebral, cardiovascular, pulmonary, abdominal, […]

error: Content is protected !
Malcare WordPress Security